MCM
MCRB icon

Manchester Capital Management’s Seres Therapeutics MCRB Stock Holding History

Manchester Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8
Closed -$1K – 528
2019
Q3 		$1K Hold
8
– – ﹤0.01% 512
2019
Q2 		$0 Hold
8
– – ﹤0.01% 610
2019
Q1 		$1K Hold
8
– – ﹤0.01% 639
2018
Q4 		$1K Hold
8
– – ﹤0.01% 515
2018
Q3 		$1K Hold
8
– – ﹤0.01% 525
2018
Q2 		$1K Buy
+8
New +$1.31K ﹤0.01% 529

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manchester Capital Management's MCRB Position: Q4 2019 in Review

Manchester Capital Management sold out of Seres Therapeutics (MCRB) in Q4 2019, closing a stake of 8 shares — an estimated $1K sold.

Manchester Capital Management first reported a position in MCRB in Q2 2018 and held it in 6 quarters. The position peaked at $1K in Q3 2019. 79 funds tracked by Wall St. Rank hold MCRB as of Q4 2019.

  • Manchester Capital Management reported no remaining Seres Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Manchester Capital Management sold 8 Seres Therapeutics shares in Q4 2019, an estimated $1K.
  • Manchester Capital Management first reported a position in Seres Therapeutics in Q2 2018 and held it in 6 quarters.
  • Manchester Capital Management's Seres Therapeutics position peaked at $1K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2019.

Based on Manchester Capital Management's 13F filing for Q4 2019, filed 10 Feb 2020.